Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Endoskopická léčba hydrocefalu u kojenců HCRN proti zkratu (ESTHI)

22. září 2026 aktualizováno: John Kestle, University of Utah

Endoskopická versus Shuntová léčba hydrocefalu u kojenců

Hydrocephalus is a potentially debilitating neurological condition that primarily affects babies under a year of age and has traditionally been treated by inserting a shunt between the brain and the abdomen. A newer endoscopic procedure offers hope of shunt- free treatment that may reduce complications over a child's life, but it is not clear if the endoscopic procedure results in similar intellectual outcome as shunt. Therefore, the investigators propose a randomized trial to compare intellectual outcome and brain structural integrity between these two treatments, to help families make the best treatment decision for their baby.

Přehled studie

Postavení

Aktivní, ne nábor

Podmínky

Intervence / Léčba

Detailní popis

The ESTHI Trial is a multi-center randomized controlled trial (RCT) comparing endoscopic third ventriculostomy with choroid plexus cauterization (ETV+CPC) and shunt in infants with hydrocephalus. The study will leverage the infrastructure of the Hydrocephalus Clinical Research Network (HCRN), a committed group of 14 leading North American pediatric neurosurgical centers with a long track-record of successful collaborative clinical research and RCTs in hydrocephalus. Optimal cognitive outcome is the primary concern of families and will, therefore, be the primary outcome. Assessment of dMRI, a validated, non-invasive method of measuring white matter microstructural integrity and structural connectivity in the developing brain, will provide further insight into the developmental consequences of these two treatments. The results of the RCT will help families determine the optimal treatment of hydrocephalus for their child.

Typ studie

Intervenční

Zápis (Aktuální)

165

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Alberta
      • Calgary, Alberta, Kanada, T3B 6A8
        • Alberta Children's Hospital
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • British Columbia Children's Hospital
    • Ontario
      • Toronto, Ontario, Kanada, M5G 1X8
        • The Hospital for Sick Children
    • Alabama
      • Birmingham, Alabama, Spojené státy, 35233
        • Children's of Alabama
    • Arizona
      • Phoenix, Arizona, Spojené státy, 85016
        • Phoenix Children's Hospital
    • California
      • Los Angeles, California, Spojené státy, 90027
        • Children's Hospital of Los Angeles
    • Colorado
      • Aurora, Colorado, Spojené státy, 80045
        • Children's Hospital Colorado
    • Connecticut
      • New Haven, Connecticut, Spojené státy, 06520
        • Yale University
    • Florida
      • Jacksonville, Florida, Spojené státy, 32207
        • Wolfson Children's Hospital
      • Orlando, Florida, Spojené státy, 32806
        • Arnold Palmer Hospital for Children
    • Indiana
      • Indianapolis, Indiana, Spojené státy, 46202
        • Trustees of Indiana University
    • Maryland
      • Baltimore, Maryland, Spojené státy, 21287
        • Johns Hopkins Children's Center
    • Missouri
      • St Louis, Missouri, Spojené státy, 63110
        • St. Louis Children's Hospital
    • Ohio
      • Columbus, Ohio, Spojené státy, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Spojené státy, 15224
        • Children's Hospital of Pittsburgh of UPMC
      • University Park, Pennsylvania, Spojené státy, 16802
        • The Pennsylvania State University
    • Tennessee
      • Nashville, Tennessee, Spojené státy, 37232
        • Monroe Carell Jr. Children's Hospital at Vanderbilt
    • Texas
      • Houston, Texas, Spojené státy, 77030
        • Texas Children's Hospital
    • Utah
      • Salt Lake City, Utah, Spojené státy, 84118
        • Primary Children's Hospital
    • Virginia
      • Richmond, Virginia, Spojené státy, 23284
        • Virginia Commonwealth University
    • Washington
      • Seattle, Washington, Spojené státy, 98105
        • Seattle Children's Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

1 den až 1 rok (Dítě)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Corrected age <104 weeks and 0 days,

    AND

  2. Child is ≥ 37 weeks post menstrual age,

    AND

  3. Child must have symptomatic hydrocephalus, defined as:

    Ventriculomegaly on MRI (frontal-occipital horn ratio (FOR) >0.45, which approximates "moderate ventriculomegaly"), and at least one of the following:

    • Head circumference >98th percentile for corrected age with either bulging fontanelle or splayed sutures
    • Upgaze paresis/palsy (sundowning)
    • CSF leak
    • Papilledema
    • Tense pseudomeningocele or tense fluid along a track
    • Vomiting or irritability, with no other attributable cause
    • Bradycardias or apneas, with no other attributable cause
    • Intracranial pressure (ICP) monitoring showing persistent elevation of pressure with or without plateau waves

    AND

  4. No prior history of shunt insertion or endoscopic third ventriculostomy (ETV) procedure (previous temporization devices and/or external ventricular drains permissible)

Exclusion Criteria:

  1. Hydrocephalus due to intraventricular hemorrhage in a child born before 37 weeks gestational age; OR

  2. Anatomy not suitable for ETV+CPC or anteriorly placed ventriculoperitoneal shunt defined as:

    • Moderate to severe prepontine adhesions on steady state free precession (SSFP) or T2 weighted fast (turbo) spin echo (FSE/TSE) MRI, which includes the following sequences: FIESTA, FIESTA-C, TrueFISP, CISS, Balanced FFE (bFFE), CUBE, SPACE, VISTA, IsoFSE, and 3D MVOX
    • Closure of one or both foramina of Monro
    • Thick floor of third ventricle (≥ 3mm)
    • Narrow third ventricle (<5mm)
    • Presence of scalp, bone, or ventricular lesions that make placement of an anterior shunt impracticable; OR
  3. Underlying condition with a high chance of mortality within 12 months; OR

  4. Hydrocephalus with loculated CSF compartments; OR

  5. Peritoneal cavity not suitable for distal shunt placement; OR

  6. Active CSF infection; OR

  7. Hydranencephaly; OR

  8. Child requires an intraventricular procedure (e.g. endoscopic biopsy) in addition to the initial first-time permanent procedure for the treatment of hydrocephalus.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: ETV+CPC

Subjects randomized to this arm will undergo an ETV+CPC procedure for treatment of Hydrocephalus

Since the early 1990s, ETV has become the main alternative to shunting for hydrocephalus. This procedure involves placing an endoscopic camera into the ventricles of the brain and creating a hole in the floor of the third ventricle to act as an internal bypass for obstructed CSF. The cauterization of choroid plexus (CPC) involves the use of a device to burn or cauterize tissue from the choroid plexus. The choroid plexus of the brain exists in the lateral ventricles, the third ventricle, and the fourth ventricle. Its main role is the production of CSF. The success of ETV alone is poor in infants, but when combined with CPC, improved results have been observed and ETV+CPC has become a safe viable option for these children.

Aktivní komparátor: Ventriculoperitoneal Shunt

Subjects randomized to this arm will undergo a Ventriculoperitoneal Shunt procedure for treatment of Hydrocephalus

The most common treatment for hydrocephalus has been the insertion of a ventriculoperitoneal shunt, which has been in popular use for over 50 years. This consists of silastic tubing attached to a valve mechanism that runs subcutaneously from the head to the abdomen. It is one of the most common procedures performed by pediatric neurosurgeons.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Bayley Scale of Infant Development-IV (Bayley-IV) Cognitive Scale score
Časové okno: 12 months post randomized surgical intervention

The primary objective is to determine, in infants <104 weeks corrected age, with hydrocephalus requiring treatment at tertiary care pediatric neurosurgery centers in North America, if treatment with ETV+CPC compared to shunt results in non-inferior cognitive outcome at 12 months from surgery, as measured by Bayley-IV Cognitive Scale score with a non-inferiority margin of 1.5. Scaled scores range from 1-19. Higher scores indicate better outcomes. Scores will also be obtained at 3 and 5 years of age.

12 months post randomized surgical intervention

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Bayley Scale of Infant Development-IV (Bayley-IV) Language Scaled Score
Časové okno: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Bayley-IV Language Scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Bayley Scale of Infant Development-IV (Bayley-IV) Motor Scaled Score
Časové okno: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Bayley-IV Motor Scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

12 months post randomized surgical intervention

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Vineland-3 Communication Domain Score
Časové okno: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Communication Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Daily Living Skills Domain Score
Časové okno: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Daily Living Skills Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Socialization Domain Score
Časové okno: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Socialization Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Motor Skills Domain Score
Časové okno: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Motor Skills Domain scores. Domain scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
Vineland-3 Adaptive Behavior Composite Score
Časové okno: 12 months post randomized surgical intervention

To determine, in the same cohort of infants, if ETV+CPC compared to shunt results in non-inferior Vineland-3 Adaptive Behavior Composite (ABC) scores. ABC scores range from 20-140. Higher scores indicate better outcomes.

12 months post randomized surgical intervention
The occurrence of treatment failure.
Časové okno: Through study completion, a maximum of 7 years.

Treatment failure is defined as obstruction, loculated compartments, overdrainage, CSF infection, or significant intraoperative complication. The rate of occurrence of each type, for the initial procedure, will be calculated. Failure can be captured at anytime during the course of the 7 year study. Occurrence between treatment arms will be compared.

Through study completion, a maximum of 7 years.
Time to failure.
Časové okno: Through study completion, a maximum of 7 years

Time to failure is the number of days in which the intervention is functionally successful. It is calculated from date of surgery to date of failure, as described in Outcome 9. Time to failure between treatment arms will be compared.

Through study completion, a maximum of 7 years
Total number of hospital admission days within 12 months after surgery
Časové okno: 12 months post randomized surgical intervention

Number of days subject is admitted to the hospital during the first 12 months following the initial surgical intervention. All hospital admissions included, regardless of reason for admission. Number of hospital admission days between treatment arms will be compared.

12 months post randomized surgical intervention
Total number of repeat surgeries within 12 months after surgery
Časové okno: 12 months post randomized surgical intervention

Number of shunt and ETV+CPC procedures during the first 12 months following the initial surgical intervention. Number of repeat surgeries between treatment arms will be compared.

12 months post randomized surgical intervention
Total number of brain imaging (CT, MRI, ultrasound) scans within 12 months after surgery
Časové okno: 12 months post randomized surgical intervention

Number of CT, MRI, and ultrasound brain scans during the first 12 months following the initial surgical intervention. Total imaging between treatment arms will be compared.

12 months post randomized surgical intervention
All major peri-operative and post-operative complications
Časové okno: Through study completion, a maximum of 7 years

Number of peri-operative and post-operative complications to include those related to CSF circulation, infection, hemorrhage, seizures, and new neurological deficits. Number of complications between treatment arms will be compared.

Through study completion, a maximum of 7 years
Brain and ventricle volume on MRI performed at 12 months after surgery
Časové okno: 12 months post randomized surgical intervention

Brain and CSF volumes will be converted to Z-scores based on previously described age- and sex-adjusted distributions and used for comparison of brain volume and growth between ETV+CPC and shunt treatment groups.

12 months post randomized surgical intervention
dMRI corpus collosum (CC) and corticospinal tract (CST) fractional anisotropy (FA) at 12 months after surgery.
Časové okno: 12 months post randomized surgical intervention

Develop dMRI maps, including fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD). Tract-based spatial statistics (TBSS) will be used for voxel-wise analyses of white matter tracts. Maps will be used to compare cerebral structural connectivity between the two treatment arms.

12 months post randomized surgical intervention
Cerebral spinal fluid myelin basic protein (MBP) levels measured at the time of ETV+CPC or shunt
Časové okno: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid myelin basic protein (MBP) levels to post-operative Bayley-IV Cognitive Scale score.

12 months post randomized surgical intervention
Cerebral spinal fluid amyloid precursor protein (APP) levels measured at the time of ETV+CPC or shunt
Časové okno: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid amyloid precursor protein (APP) to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Cerebral spinal fluid NCAM-1 levels measured at the time of ETV+CPC or shunt
Časové okno: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid NCAM-1 levels to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Cerebral spinal fluid glial fibrillary acid protein (GFAP) levels measured at the time of ETV+CPC or shunt
Časové okno: 12 months post randomized surgical intervention

Examine correlations of cerebral spinal fluid glial fibrillary acid protein (GFAP) to post-operative Bayley-IV Cognitive Scale score

12 months post randomized surgical intervention
Wechsler Preschool & Primary Scale of Intelligence (WPPSI) Scores
Časové okno: At 5 years of age

To determine, in infants who reach 5 years of age before the end of the study, if ETV+CPC compared to shunt results in non-inferior WPPSI scaled scores. Scaled scores range from 1-19. Higher scores indicate better outcomes.

At 5 years of age
Health related quality of life (HRQoL) measurements
Časové okno: 12 months post randomized surgical intervention, and at 3 and 5 years of age

To compare health-related quality of life (HRQoL), as measured by vi-sual analogue scales (VAS), Health Utilities Preschool (HuPS), and the Hydrocephalus Outcome Questionnaire (HOQ), between treatment arms.

12 months post randomized surgical intervention, and at 3 and 5 years of age

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Studijní židle: John Kestle, MD, University of Utah
  • Vrchní vyšetřovatel: Abhaya Kulkarni, MD, University of Toronto
  • Vrchní vyšetřovatel: David Limbrick, MD, Washington University School of Medicine
  • Vrchní vyšetřovatel: Richard Holubkov, PhD, University of Utah

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

21. července 2020

Primární dokončení (Odhadovaný)

30. května 2027

Dokončení studie (Odhadovaný)

31. srpna 2027

Termíny zápisu do studia

První předloženo

27. října 2019

První předloženo, které splnilo kritéria kontroly kvality

22. listopadu 2019

První zveřejněno (Aktuální)

26. listopadu 2019

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

25. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

22. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • HCRN 012
  • 1U01NS107486-01A1 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

After subject enrollment and 5 year follow up have been completed, we will prepare a final study database for analysis. A releasable database will be produced and completely de-identified in accordance with the definitions provided in the Health insurance Portability and Accountability Act (HIPAA). Namely, all identifiers specified in HIPAA will be recoded in a manner that will make it impossible to deduce or impute the specific identity of any patient. The database will not contain any institutional identifiers. We will also prepare a data dictionary that provides a concise definition of every data element included in the database. If specific data elements have idiosyncrasies that might affect interpretation or analysis, this will be discussed in the dictionary document.

In accordance with policies determined by the investigators and funding sponsors, the releasable database will be provided to users in electronic form.

Časový rámec sdílení IPD

Within one year of primary publication or within 18 months of the last study visit of the last subject, whichever occurs first.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .